The emergence of the Cicada variant, designated BA.3.2, marks a significant moment in the ongoing battle against COVID-19. Before this development, public health officials and the general population had hoped that existing vaccines would continue to provide robust protection against the virus, especially as the Omicron variants had already shown some level of containment. However, the arrival of the Cicada variant in the UK has shifted expectations and raised new concerns.
First detected in South Africa in November 2024, the Cicada variant has since spread to 23 countries, including the UK. This variant is particularly notable for its 70 to 75 genetic changes in its spike protein, which may affect how the virus interacts with the immune system. As of February 2026, the variant has been confirmed in 24 countries, with weekly detections in Denmark, Germany, and the Netherlands rising to make up around 30% of COVID-19 sequences reported in those nations from November 2025 to January 2026.
Who is involved
The direct effects of the Cicada variant are being felt across various sectors, particularly in healthcare. Symptoms associated with this variant include a painful sore throat, fever, cough, fatigue, and nasal congestion, which can complicate diagnosis and treatment. The National Health Service (NHS) in the UK is preparing for potential increases in hospitalizations, with estimates suggesting that the 2024-25 respiratory virus season could see between 390,000 and 550,000 hospitalizations and 45,000 to 64,000 deaths.
Experts are weighing in on the implications of this new variant. Kyle B. Enfield, a prominent epidemiologist, noted, “Because it’s significantly different, the current COVID-19 vaccine may not be as effective.” Ian Budd, another expert in virology, emphasized, “What’s different about it is the number of mutations it carries, particularly on the part of the virus that attaches to your cells.” This raises questions about the long-term effectiveness of current vaccines against the Cicada variant.
Despite these concerns, there is some reassurance from health authorities. The Centers for Disease Control and Prevention (CDC) has indicated that the Cicada strain “could be associated with seasonal increases in COVID-19 activity,” but it has also stated, “There’s no sign so far that BA.3.2, nicknamed Cicada, is any more dangerous or causes more severe disease than the variants that were circulating in the winter of 2025-26.” This perspective is crucial for public health messaging, as it helps to mitigate panic while emphasizing the need for vigilance.
As the situation evolves, the community remains on high alert. The exact impact of the Cicada variant on public health remains unclear due to limited genomic detection and surveillance capacities in many countries. Additionally, the long-term effectiveness of current vaccines against this variant is uncertain. Details remain unconfirmed.
In conclusion, the emergence of the Cicada variant in the UK serves as a reminder of the unpredictable nature of the COVID-19 pandemic. As communities come together to navigate this new challenge, the importance of vaccination, public health measures, and staying informed remains paramount. The road ahead may be uncertain, but collective efforts can help mitigate the impact of this new variant on public health.
